Quantum BioPharma announced that it has entered into a binding letter of intent with Allucent to support the planned Phase 2 clinical trial of Lucid-MS for the treatment of multiple sclerosis. The planned Phase 2 trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with MS. Quantum BioPharma expects to initiate the Phase 2 trial in the second quarter of 2026, subject to regulatory approvals and finalization of the clinical trial design and operational arrangements. Under the terms of the LOI, Allucent will provide comprehensive clinical trial services designed to support efficient execution and data integrity throughout the study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial
- Quantum BioPharma Posts Strong 2025 Results, Extends Cash Runway and Advances MS and Alcohol Health Programs
- Quantum BioPharma Taps MS Expert to Lead Phase 2 Trial of Lucid-MS
- Is QNTM a Buy, Before Earnings?
- Quantum BioPharma Wins Peer-Reviewed Validation for Unbuzzd Alcohol-Relief Supplement